peptidefix

Tirzepatide

Also: Mounjaro, Zepbound, LY3298176

Metabolic & weight
Legal status United KingdomApproved medicineUnited StatesApproved medicineAustraliaPrescription only
Research on peptidefix

10 papers: 9 human studies, 1 animal study.

Listed suppliers United Kingdom2United States4Australia4 Europe3
Checked 2026-11-03

Legal status as understood on this date. Listed, not endorsed. How we list.

Summary

Tirzepatide is a synthetic peptide that activates two hormone receptors at once: GIP and GLP-1, both involved in insulin release and appetite. It is a licensed medicine in the UK, the US and Australia, which makes it the most heavily regulated substance covered on this site, and it has the largest trial programme of anything here.

What it targets

Acting on the GIP and GLP-1 receptors together influences insulin secretion, appetite and how full a meal feels. In the SURMOUNT-1 trial, 2,539 adults with obesity, or overweight plus a weight-related condition but not diabetes, were randomised to one of three tirzepatide levels or placebo for 72 weeks; both co-primary endpoints, percentage weight change and the proportion losing at least 5 percent of body weight, favoured tirzepatide at every level. A three-year extension followed the participants who also had prediabetes, reporting weight change to week 176, progression to type 2 diabetes and what happened over 17 weeks off treatment. Two further phase 3 trials tested it in moderate-to-severe obstructive sleep apnoea with obesity, measuring breathing interruptions per hour of sleep, and a 731-person trial tested it in heart failure with preserved ejection fraction and obesity against cardiovascular outcomes and quality of life. The programme is funded by the manufacturer throughout.

body weight in obesity (phase 3, 2,539 people)progression to type 2 diabetes (3-year extension)obstructive sleep apnoea with obesity (two phase 3 trials)heart failure with preserved ejection fraction (731 people)

Clinical Research

Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial
Green DJ, Haynes A, Underwood DR, et al. (2026). Nature Medicine. human 120 adults aged 50 to 70 with overweight or obesity, all treated with tirzepatide; single-centre randomised trial of resistance training versus usual activity (T-REx, ACTRN12623001236684), 40 weeks
Effects of tirzepatide on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis
Eisa N, Khoury M (2026). The Journal of Clinical Endocrinology & Metabolism. meta-analysis 7 studies (5 RCTs, 2 observational), 5,406 participants
Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity
Brancato D, et al. (2026). Journal of Diabetes and Its Complications. human humans, n=122, retrospective observational study, 24 weeks
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study (ESTATE)
Iwamoto et al.; East Shizuoka Tirzepatide study collaborators (2026). Endocrine Journal. human humans, n=88, multicentre retrospective single-arm observational study, 24 weeks
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-kB signaling
He Y, Ma T, Xing H, et al. (2026). European Journal of Pharmacology. animal diet-induced male C57BL/6J mice (n not stated in abstract), plus RAW264.7 macrophage and HepG2 liver cell lines
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). New England Journal of Medicine. human 2,539 adults with obesity, or overweight with a weight-related complication, excluding diabetes; phase 3, double-blind, placebo-controlled, 72 weeks
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al. (2025). New England Journal of Medicine. human 1,032 SURMOUNT-1 participants who had both obesity and prediabetes, followed to 176 weeks plus a 17-week period off treatment
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra A, Grunstein RR, Fietze I, et al. (2024). New England Journal of Medicine. human adults with moderate-to-severe obstructive sleep apnoea and obesity across two phase 3 trials, one in people not using positive airway pressure and one in people already using it; 52 weeks
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer M, Zile MR, Kramer CM, et al. (2025). New England Journal of Medicine. human 731 patients with heart failure, an ejection fraction of at least 50 percent and obesity; international, double-blind, placebo-controlled, at least 52 weeks
Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes
Lin CL, Lin KC, Yu JM, et al. (2026). Nature Communications. human humans, 14,118 matched pairs, retrospective cohort from an international federated electronic health-record network, adults with atrial fibrillation and type 2 diabetes

All research on Tirzepatide →

Suppliers stocking Tirzepatide

13 of the 49 listed suppliers. Each row opens its full listing.

American Peptides United States Products are sold for Research Use Only and not for Human Consumption. Not for human or veterinary use. Au Peptide Labs Australia For laboratory research use only. Not for human consumption. Aussie Peptides Australia Research use only. Statements have not been evaluated by the TGA. We do not ship internationally at this time. Baltic BioLabs Lithuania For laboratory research only, not for human or veterinary use. Baltic Peptides Lithuania All products are supplied strictly for laboratory research use only. Not for human or veterinary use. British Peptide Labs United Kingdom For research use only. Not for human or veterinary use. Sold strictly for in-vitro laboratory research; not for diagnosis or treatment. Eurolabs Peptides Germany For research purposes only. Not for human consumption. Next Gen Peptides Australia Not for human consumption. Peak Lab Peptides United States All products on this site are for research and development use only. Products are not for human consumption of any kind. Prism Labs United States All products sold by Prism Labs are intended strictly for in-vitro research, laboratory experimentation, and educational purposes. Products are not intended for human or veterinary use. Research Peptide United Kingdom Supplied strictly for research and laboratory use only and not for human or veterinary consumption. Synapse Peptides Australia Australia All products are supplied strictly for research purposes only and are not intended for human or veterinary use. Xeno Peptides United States All products are for laboratory and research use only — not for human consumption or clinical application.